VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS VECTOR FOR THE RECOMBINANT EXPRESSION OF PROTEINS IN MAMMALIAN CELLS

Main Article Content

Authors

A.Zh. Baltabekova

National Center for Biotechnology, 13/5, Korgalzhyn Road, Astana, 010000, Kazakhstan

Zh.S. Shagyrova

National Center for Biotechnology, 13/5, Korgalzhyn Road, Astana, 010000, Kazakhstan

Y.G. Kim

National Center for Biotechnology, 13/5, Korgalzhyn Road, Astana, 010000, Kazakhstan

M.S. Voikov

National Center for Biotechnology, 13/5, Korgalzhyn Road, Astana, 010000, Kazakhstan

E. Zhiyenbay

National Center for Biotechnology, 13/5, Korgalzhyn Road, Astana, 010000, Kazakhstan

A.V. Shustov

National Center for Biotechnology, 13/5, Korgalzhyn Road, Astana, 010000, Kazakhstan

Abstract

Venezuelan equine encephalomyelitis virus (VEE) is a well-studied member of the genus Alphavirus in the family Togaviridae. The VEE virus is a popular vector for gene delivery in cell culture as well as for heterologous expression of recombinant proteins in cultures of vertebrate and insect cells. All VEE RNA synthesis occurs in the cytoplasm and during the course of recombinant protein expression from a gene cloned into the VEE genome, a number of molecular processes are excluded, which may otherwise represent a bottleneck in the expression system. Complementary DNA (cDNA) representing the full-length VEE genome was assembled and cloned into an Escherichia coli plasmid under the control of the SP6 RNA polymerase promoter. The gene encoding GFP was engineered into the VEE genome under the control of a synthetic copy of a viral 26S subgenomic RNA promoter. The RNA transcript of the recombinant virus was transfected into BHK-21 cells and by 36 h post-transfection, almost all cells in the culture exhibited bright GFP fluorescence. Titres of the virus produced in the transfected culture were measured for 5 days and found to be 8.4*105 TCID50 24 h post-transfection and 2.9*108 TCID50 by 3 days post-transfection.

This article illustrates the basic steps of constructing a VEE-based vector and furthermore, demonstrates the rescue of the recombinant VEE variant engineered to produce model recombinant protein GFP. The VEE vector may be applicable in biopharmaceutical production in Kazakhstan.

Keywords

alphavirus, eukaryotic expression, vector, transient expression, virus rescue, complementary DNA (cDNA)

Article Details

References

Baldi L., Hacker D.L., Adam M., Wurm F.M. Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol.Lett., 2007, no. 5, pp. 677-684.

Conceicao M.M., Tonso A., Freitas C.B., Pereira C.A. Viral antigen production in cell cultures on microcarriers Bovine parainfluenza 3 virus and MDBK cells. Vaccine, 2007, no. 45, pp. 7785-7795.

Walsh G. Post-translational modifications of protein biopharmaceuticals. Drug Discov. Today, 2010, no. 17, pp. 773-780.

Kerrigan J.J., Xie Q., Ames R.S., Lu Q. Production of protein complexes via co-expression.Protein Expr.Purif., 2011, no. 1, pp.1-14.

De Jesus M., Wurm F.M. Manufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors.Eur. J. Pharm. Biopharm., 2011, no. 2, pp. 184-188.

Geisse S., Henke M. Large-scale transient transfection of mammalian cells: a newly emerging attractive option for recombinant protein production.J. Struct. Funct.Genomics., 2005, no. 3, pp. 165-170.

Pradeau-Aubreton K., Ruff M., Garnier J.M., Schultz P., Drillien R. Vectors for recombinational cloning and gene expression in mammalian cells using modified vaccinia virus Ankara.Anal.Biochem., 2010, no. 1, pp. 103-105.

Pham P.L., Kamen A., Durocher Y. Large-scale transfection of mammalian cells for the fast production of recombinant protein.Mol. Biotechnol., 2006, no. 2, pp. 225-237.

Quetglas J.I., Ruiz-Guillen M., Aranda A., Casales E., Bezunartea J., Smerdou C. Alphavirus vectors for cancer therapy.Virus Res., 2010, no. 2, pp. 179-196.

Trowitzsch S., Bieniossek C., Nie Y., Garzoni F., Berger I. New baculovirus expression tools for recombinant protein complex production J. Struct. Biol., 2010, no. 1, pp. 45-54.

Gomez-Casado E., Gomez-Sebastian S., Nunez M.C., Lasa-Covarrubias R., Martinez-Pulgarin S., Escribano J.M. Insect larvae biofactories as a platform for influenza vaccine production.Protein Expr.Purif., 2011, no. 1, pp. 35-43.

Kost T.A., Condreay J.P., Jarvis D.L. Baculovirus as versatile vectors for protein expression in insect and mammalian cells.Nat. Biotechnol., 2005, no. 5, pp. 567-575.

Chikkanna-Gowda C.P., McNally S., Sheahan B.J., Fleeton M.N., Atkins G.J. Inhibition of murine K-BALB and CT26 tumour growth using a Semliki Forest virus vector with enhanced expression of IL-18.Oncol. Rep., 2006, no. 4, pp. 713-719.

Chikkanna-Gowda C.P., Sheahan B.J., Fleeton M.N., Atkins G.J. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12.Gene Ther., 2005, no. 16, pp. 1253-1263.

Quetglas J.I., Fioravanti J., Ardaiz N. A Semliki forest virus vector engineered to express IFNalpha induces efficient elimination of established tumors.Gene Ther., 2012, no. 3, pp. 271-278.

Rodriguez-Madoz J.R., Prieto J., Smerdou C. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol. Ther., 2005, no. 1, pp. 153-163.